DE602004007284D1 - Pyrimidine als inhibitoren von phosphoinositid-3-kinasen (pi3k) - Google Patents

Pyrimidine als inhibitoren von phosphoinositid-3-kinasen (pi3k)

Info

Publication number
DE602004007284D1
DE602004007284D1 DE602004007284T DE602004007284T DE602004007284D1 DE 602004007284 D1 DE602004007284 D1 DE 602004007284D1 DE 602004007284 T DE602004007284 T DE 602004007284T DE 602004007284 T DE602004007284 T DE 602004007284T DE 602004007284 D1 DE602004007284 D1 DE 602004007284D1
Authority
DE
Germany
Prior art keywords
pyrimidines
phosphoinositide
pi3k
kinases
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004007284T
Other languages
English (en)
Other versions
DE602004007284T2 (de
Inventor
Michael Kevin Connolly
Rocco Dean Gogliotti
Mark Stephen Plummer
Melean Visnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE602004007284D1 publication Critical patent/DE602004007284D1/de
Application granted granted Critical
Publication of DE602004007284T2 publication Critical patent/DE602004007284T2/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
DE602004007284T 2003-10-31 2004-10-19 PYRIMIDINE ALS INHIBITOREN VON PHOSPHOINOSITID-3-KINASEN (PI3Ks) Expired - Fee Related DE602004007284T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51659103P 2003-10-31 2003-10-31
US516591P 2003-10-31
PCT/IB2004/003417 WO2005042519A1 (en) 2003-10-31 2004-10-19 Pyrimidines as inhibitors of phosphoinositide -3-kinases (pi3k)

Publications (2)

Publication Number Publication Date
DE602004007284D1 true DE602004007284D1 (de) 2007-08-09
DE602004007284T2 DE602004007284T2 (de) 2008-02-28

Family

ID=34549554

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004007284T Expired - Fee Related DE602004007284T2 (de) 2003-10-31 2004-10-19 PYRIMIDINE ALS INHIBITOREN VON PHOSPHOINOSITID-3-KINASEN (PI3Ks)

Country Status (9)

Country Link
US (1) US20090227587A1 (de)
EP (1) EP1682532B1 (de)
JP (1) JP2007509924A (de)
AT (1) ATE365732T1 (de)
BR (1) BRPI0415860A (de)
CA (1) CA2543608A1 (de)
DE (1) DE602004007284T2 (de)
ES (1) ES2285517T3 (de)
WO (1) WO2005042519A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067901A2 (en) * 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
MX2010010209A (es) 2008-03-18 2010-10-05 Merck Sharp & Dohme 4-hidroxipirimidina-5-carboxamidas sustituidas.
DK2448927T3 (da) * 2009-07-02 2014-06-16 Sanofi Sa Hidtil ukendte (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amidderivater, fremstilling deraf og farmaceutisk anvendelse deraf som akt-phosphoryleringshæmmere
WO2011065800A2 (ko) * 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
KR101301533B1 (ko) 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
EP2914260A1 (de) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur vorbeugung des antiphospholipid-syndroms (aps)
AU2019301628A1 (en) * 2018-07-09 2021-01-28 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3042601A (en) * 2000-01-24 2001-07-31 Thrombogenix Pty Ltd Therapeutic morpholino-substituted compounds

Also Published As

Publication number Publication date
US20090227587A1 (en) 2009-09-10
EP1682532A1 (de) 2006-07-26
CA2543608A1 (en) 2005-05-12
EP1682532B1 (de) 2007-06-27
WO2005042519A1 (en) 2005-05-12
BRPI0415860A (pt) 2007-01-09
ES2285517T3 (es) 2007-11-16
ATE365732T1 (de) 2007-07-15
JP2007509924A (ja) 2007-04-19
DE602004007284T2 (de) 2008-02-28

Similar Documents

Publication Publication Date Title
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE602005002562D1 (de) Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
TW200612950A (en) Quinazolinedione derivatives as PARP inhibitors
TW200608977A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
SG154433A1 (en) Phthalazine derivatives as parp inhibitors
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
ATE517896T1 (de) P38-kinase-inhibitoren
EA200501333A1 (ru) 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
IS2855B (is) 4-anilínókínasólínafleiður sem andfjölgunarefni
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
HRP20050714B1 (hr) Aminoheteroarilni spojevi kao inhibitori proteinskih kinaza
UA91002C2 (ru) 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
MXPA05012894A (es) Benzofuranos 3-sustituidos como agentes terapeuticos.
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
PL375360A1 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
DE602004020070D1 (de) Thienopyrimidin-derivate als kaliumkanal-inhibitoren
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
ATE365735T1 (de) Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
MXPA05012953A (es) Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: CONNOLLY, MICHAEL KEVIN, ANN ARBOR, MI 48105, US

Inventor name: VISNICK, MELEAN, ANN ARBOR, MI 48105, US

Inventor name: GOGLIOTTI, ROCCO DEAN, ANN ARBOR, MI 48105, US

Inventor name: PLUMMER, MARK STEPHEN, ANN ARBOR, MI 48105, US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee